Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma
NCT03309111
Age 18 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
This study is trying to see if a new medicine called ISB 1342 is safe and effective for people with a certain kind of cancer called multiple myeloma. They also want to learn how the medicine works in the body and if it causes any immune reactions.
This study is trying to see if a new medicine called ISB 1342 is safe and effective for people with a certain kind of cancer called multiple myeloma. They also want to learn how the medicine works in the body and if it causes any immune reactions.
Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to assess safety, efficacy, pharmacokinetic (PK)/pharmacodynamic (PD), and immunogenicity with ISB 1342 in subjects with relapsed/refractory multiple myeloma.
The purpose of this study is to assess safety, efficacy, pharmacokinetic (PK)/pharmacodynamic (PD), and immunogenicity with ISB 1342 in subjects with relapsed/refractory multiple myeloma.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
